AstraZeneca maintained revenue growth in the second quarter of 2026 as demand for its oncology medicines continued to offset pressure across other parts of the business. Revenue rose 6% year-on-year to $15.4bn in the second quarter, bringing first-half revenue to $30.7bn, up 9% on the same period last year. Supported by its first-half performance, AstraZeneca reaffirmed its guidance for mid-to-high single-digit revenue growth and low double-digit growth in core earnings per share for 2026. Oncology fuels uptickThe strongest contribution came from the company’s oncology business, where revenue increased 16% in the second quarter, supported by continued growth from durvalumab, trastuzumab deruxtecan and acalabrutinib. Even so, continued uptake of AstraZeneca’s newer medicines helped sustain overall revenue growth.